These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 14689108)

  • 21. Systolic hypertension.
    Nash DT
    Geriatrics; 2006 Dec; 61(12):22-8. PubMed ID: 17184139
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drug therapy for hypertension in hemodialysis patients.
    Hörl MP; Tepel M
    Minerva Med; 2005 Aug; 96(4):277-85. PubMed ID: 16179894
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nebivolol: a third-generation beta-blocker for hypertension.
    Cheng JW
    Clin Ther; 2009 Mar; 31(3):447-62. PubMed ID: 19393838
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug therapy for hypertension in hemodialysis patients.
    Hörl MP; Hörl WH
    Semin Dial; 2004; 17(4):288-94. PubMed ID: 15250920
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A 16-week, randomized, double-blind, placebo-controlled, crossover trial to quantify the combined effect of an angiotensin-converting enzyme inhibitor and a beta-blocker on blood pressure reduction.
    Wald DS; Law M; Mills S; Bestwick JP; Morris JK; Wald NJ
    Clin Ther; 2008 Nov; 30(11):2030-9. PubMed ID: 19108791
    [TBL] [Abstract][Full Text] [Related]  

  • 26. RAS inhibition in hypertension.
    Ibrahim MM
    J Hum Hypertens; 2006 Feb; 20(2):101-8. PubMed ID: 16397519
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Fewer cases of stroke, atrial fibrillation, diabetes and renal insufficiency. Good treatment of hypertension is more than lowering of blood pressure].
    Baumgart P
    MMW Fortschr Med; 2008 Jan; 150(1-2):52-3. PubMed ID: 18300647
    [No Abstract]   [Full Text] [Related]  

  • 28. The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: part II - therapy.
    Khan NA; McAlister FA; Lewanczuk RZ; Touyz RM; Padwal R; Rabkin SW; Leiter LA; Lebel M; Herbert C; Schiffrin EL; Herman RJ; Hamet P; Fodor G; Carruthers G; Culleton B; DeChamplain J; Pylypchuk G; Logan AG; Gledhill N; Petrella R; Campbell NR; Arnold M; Moe G; Hill MD; Jones C; Larochelle P; Ogilvie RI; Tobe S; Houlden R; Burgess E; Feldman RD;
    Can J Cardiol; 2005 Jun; 21(8):657-72. PubMed ID: 16003449
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Usefulness of the alpha1-blocker doxazosin as a third-line antihypertensive drug.
    Ohta Y; Tsuchihashi T; Onaka U; Eto K; Ueno M
    Hypertens Res; 2007 Apr; 30(4):301-6. PubMed ID: 17541208
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Managing hypertension in high-risk patients: lessons and promises from the STRATHE and ADVANCE trials.
    Waeber B
    J Hypertens Suppl; 2006 May; 24(3):S19-27. PubMed ID: 16723862
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anaemia due to ACE inhibitors and losartan in patients with renal failure.
    Prescrire Int; 1999 Dec; 8(44):179-80. PubMed ID: 11503817
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The future of antihypertensive treatment.
    Israili ZH; Hernández-Hernández R; Valasco M
    Am J Ther; 2007; 14(2):121-34. PubMed ID: 17414579
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Perindopril/indapamide combination in the first-line treatment of hypertension and end-organ protection.
    Gosse P
    Expert Rev Cardiovasc Ther; 2006 May; 4(3):319-33. PubMed ID: 16716093
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of manidipine/delapril versus losartan/hydrochlorothiazide fixed combinations in patients with hypertension and diabetes.
    Roca-Cusachs A; Schmieder RE; Triposkiadis F; Wenzel RR; Laurent S; Kohlmann O; Fogari R;
    J Hypertens; 2008 Apr; 26(4):813-8. PubMed ID: 18327093
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Benefits of angiotensin converting enzyme inhibition and angiotensin II receptor antagonists in hypertension.
    Conlin PR
    J Med Liban; 2000; 48(6):382-6. PubMed ID: 11503531
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A comparative review of the efficacy of antihypertensive agents on 24 h ambulatory blood pressure.
    Lacourcière Y; Poirier L; Lefebvre J
    Can J Cardiol; 2000 Sep; 16(9):1155-66. PubMed ID: 11021959
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Treatment of hypertension: angiotensin-II antagonists potentially better than beta-blockers in the occurrence of cardiovascular and cerebrovascular damage; the LIFE study in perspective].
    Dorhout Mees EJ
    Ned Tijdschr Geneeskd; 2003 Mar; 147(11):521-2; author reply 522. PubMed ID: 12677953
    [No Abstract]   [Full Text] [Related]  

  • 38. AT(1)-receptor blockers: differences that matter.
    Gradman AH
    J Hum Hypertens; 2002 Aug; 16 Suppl 3():S9-S16. PubMed ID: 12140723
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The role of angiotensin II inhibitors in arterial hypertension: clinical trials and guidelines].
    Mancia G; Grassi G
    Ann Ital Med Int; 2000; 15(1):92-5. PubMed ID: 10842897
    [TBL] [Abstract][Full Text] [Related]  

  • 40. AT1 receptor blockers--cost-effectiveness within the South African context.
    Anderson AN; Wessels F; Moodley I; Kropman K
    S Afr Med J; 2000 May; 90(5):494-8. PubMed ID: 10901822
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.